BioSpace News Archive

Deals

GlaxoSmithKline Rumored to be Mulling $1.65B Bid for Partner Vectura

Speculation around a possible bid has mounted in recent months.

January 16, 2018
·
2 min read
·
Mark Terry
Drug Development

Stock Tanks as Bay Area Eiger Discontinues PAD Drug After Phase II Trial Flop

Shares of Eiger have plunged more than 47 percent this morning after the company announced it is terminating its experimental PAH treatment ubenimex after it flopped its mid-stage study.

January 16, 2018
·
2 min read
·
Alex Keown
BioMidwest

Why This Mostly-Unheard of Colorado Biotech Could Hit $1B in Revenue by 2025

Leah Rush Cann, an analyst with Oppenheimer, launched coverage of this biotech citing the possibility it could exceed $1.2B in revenue by 2025.

January 16, 2018
·
2 min read
·
Mark Terry
Biotech Bay

How 2017 Was Intuitive Surgical’s Year

2017 was a banner year for the leader in robotic surgery. Look and see why investors couldn’t have asked for much more.

January 16, 2018
·
1 min read
Policy

Starkey Hearing’s Former Execs on Trial for Embezzlement, Fraud

Starkey’s longtime former president Jerry Ruzicka, CFO Scott Nelson and vice president of human resources Larry Miller were all fired in September 2015.

January 16, 2018
·
1 min read
Suzhou Zelgen Biosciences Completes $62M B Round

Suzhou Zelgen Biosciences completed a $62M series B financing to support its portfolio of small molecule and biologic drug candidates.

January 16, 2018
·
1 min read
Suzhou’s Innovent Plans Capital Raise Followed by $200M IPO

Innovent Biologics of Suzhou is planning a pre-IPO round and then an IPO for $200M in late 2018.

January 16, 2018
·
1 min read
Job Trends

Regeneron Keeps Science at the Center

Thirty years ago, neurologist Leonard S. Schliefer, MD, PhD, founded Regeneron, a life sciences company dedicated to discovering, developing and bringing new medications to the patients who need them.

January 16, 2018
·
3 min read
·
Jennifer Fink